Vis enkel innførsel

dc.contributor.authorEvans, Dafydd Gareth
dc.contributor.authorHarkness, Elaine F.
dc.contributor.authorHowell, Anthony
dc.contributor.authorWilson, Mary
dc.contributor.authorHurley, Emma
dc.contributor.authorHolmen, Marit Muri
dc.contributor.authorTharmaratnam, Kukatharmini
dc.contributor.authorHagen, Anne Irene
dc.contributor.authorLim, Yit Yoong
dc.contributor.authorMaxwell, Anthony James
dc.contributor.authorMøller, Pål
dc.identifier.citationHereditary Cancer in Clinical Practice. 2016, 14 (8)en_US
dc.description.abstractBackground The addition of annual MRI screening to mammography has heightened optimism that intensive screening along with improved treatments may substantially improve life expectancy of women at high risk of breast cancer. However, survival data from BRCA2 mutation carriers undergoing intensive combined breast screening are scarce. Methods We have collated the results of screening with either annual mammography or mammography with MRI in female BRCA2 mutation carriers in Manchester and Oslo and use a Manchester control group of BRCA2 mutation carriers who had their first breast cancer diagnosed without intensive screening. Results Eighty-seven BRCA2 mutation carriers had undergone combined (n = 34) or mammography (n = 53) screening compared to 274 without such intensive screening. Ten year breast cancer specific survival was 100 % in the combined group (95 % CI 82.5–100 %) and 85.5 % (95 % CI 72.6–98.4 %) in the mammography group compared to 74.6 % (95 % CI 66.6–82.6 %) in the control group. Better survival was driven by lymph node status (negative in 67 % of screened vs 39 % of unscreened women; p < 0.001) and a significantly greater proportion of intensively screened women had invasive breast cancers <2 cm at diagnosis (74.6 % vs 50.4 %; p = 0.002). Conclusion Intensive combined breast cancer screening with annual MRI and mammography appears to improve survival from breast cancer in BRCA2 mutation carriers. Data from larger groups are required to confirm the effectiveness of combined screening in BRCA2 carriers.en_US
dc.publisherBioMed Centralen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleIntensive breast screening in BRCA2 mutation carriers is associated with reduced breast cancer specific and all cause mortalityen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.source.journalHereditary Cancer in Clinical Practiceen_US
dc.description.localcodeOpen Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal